➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
McKinsey
Harvard Business School
Baxter
Dow

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SOMATROPIN RECOMBINANT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Somatropin Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006143 ↗ Growth Hormone Treatment of Children With HIV-Associated Growth Failure Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A 1969-12-31 The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00006143 ↗ Growth Hormone Treatment of Children With HIV-Associated Growth Failure Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to determine the effectiveness of recombinant human growth hormone (r-hGH) on growth in HIV-infected children. Studies have shown that HIV-infected children do not grow at a normal rate and are shorter than HIV-uninfected children who are the same age. Growth hormone has been used for many years to treat children with growth hormone deficiency and has been safe and effective in helping them to grow normally. The growth hormone to be used in this study, r-hGH, is an investigational hormone (not yet approved by the Food and Drug Administration [FDA]) made in the laboratory. It has helped HIV-positive adults gain weight and improve their physical performance. This study has been changed to include a needle-free device for drug delivery which will improve patient comfort and acceptability. Patients will no longer receive growth hormone through traditional needles but through a needle-free device.
NCT00050921 ↗ Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 This study is designed to evaluate the ability of growth hormone (GH, also known as somatropin) to increase CD4+ cell counts in patients taking anti-HIV drugs. The study is targeted toward patients with low levels of HIV who continue to have low CD4+ cell counts.
NCT00079742 ↗ A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis Completed Genentech, Inc. Phase 2 2003-09-01 This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.
NCT00102817 ↗ Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children Completed Novo Nordisk A/S Phase 3 2003-05-01 This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.
NCT00109473 ↗ Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Genentech, Inc. Phase 2 2005-04-01 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
NCT00109473 ↗ Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Children's Hospital Medical Center, Cincinnati Phase 2 2005-04-01 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Somatropin Recombinant

Condition Name

Condition Name for Somatropin Recombinant
Intervention Trials
Growth Hormone Disorder 24
Growth Hormone Deficiency 22
Adult Growth Hormone Deficiency 16
Genetic Disorder 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Somatropin Recombinant
Intervention Trials
Dwarfism, Pituitary 60
Endocrine System Diseases 38
Dwarfism 20
Turner Syndrome 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Somatropin Recombinant

Trials by Country

Trials by Country for Somatropin Recombinant
Location Trials
United States 220
France 26
Japan 25
Germany 23
China 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Somatropin Recombinant
Location Trials
New York 14
Texas 12
Massachusetts 12
California 12
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Somatropin Recombinant

Clinical Trial Phase

Clinical Trial Phase for Somatropin Recombinant
Clinical Trial Phase Trials
Phase 4 20
Phase 3 53
Phase 2/Phase 3 3
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Somatropin Recombinant
Clinical Trial Phase Trials
Completed 91
Terminated 12
Not yet recruiting 9
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Somatropin Recombinant

Sponsor Name

Sponsor Name for Somatropin Recombinant
Sponsor Trials
Novo Nordisk A/S 52
Pfizer 14
Eli Lilly and Company 12
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Somatropin Recombinant
Sponsor Trials
Industry 129
Other 61
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Harvard Business School
Boehringer Ingelheim
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.